1 Contributo su Rivista

1 Contributo su Rivista: [42208] Home page macrotipologia

Sfoglia

Prodotti recenti

ODISSEY: A MULTICENTER, OBSERVATIONAL STUDY OF MULTIPLE MYELOMA ITALIAN PATIENTS WHO DISCONTINUED THERAPY IN CLINICAL PRACTICE

Introduction. Nowadays continuous treatment until disease progression or unacceptable toxicity remains the main approach in multiple myeloma (MM). However, prolonged exposure may lead to cumulative toxicity, treatment fatigue and quality-of-life impairment. Indeed, in clinical practice, a not negligible number of patients discontinues therapy due to medical, personal, or logistic reasons. Recent evidence from time-limited regimens has renewed interest in whether discontinuation may be feasibl...

Frailty and Fitness in Older Adults With Acute Myeloid Leukemia: From Chronological Age to Multiparametric Assessment

Acute Myeloid Leukemia predominantly affects older adults, who often present with comorbidities, functional impairment, and frailty, limiting eligibility for intensive chemotherapy or allogeneic transplantation. Historically, treatment options were restricted to hypomethylating agents, low-dose cytarabine, hydroxyurea, or supportive care, with poor outcomes. The introduction of hypomethylating agents combined with Venetoclax and the availability of targeted therapies have expanded therapeutic...

Extranodal Marginal Zone Lymphoma: Integrating Etiology, Microenvironment, and Genetics Into Clinical Decision-Making

Extranodal marginal zone lymphoma (EMZL) represents a unique paradigm among indolent B-cell neoplasms, in which lymphomagenesis is frequently driven by chronic antigenic stimulation within tissue-specific microenvironments. Persistent infectious or autoimmune triggers promote the development of ectopic lymphoid tissue and sustain B-cell activation, while recurrent genetic alterations—most prominently those that converge on NF-κB signaling—enable progressive escape from antigen dependence. Thi...

REAL-LIFE EXPERIENCE WITH THE POLA-R-CHP REGIMEN IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): A RETROSPECTIVE ANALYSIS

Historically, R-CHOP regimen has been the standard first line treatment for diffuse large B-cell lymphoma (DLBCL). The introduction of polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (POLA-R-CHP) has shown a progression-free survival benefit in the POLARIX trial, particularly among patients with high IPI score. However, real-world data on efficacy and toxicity profile of this combination regimen remain limited. Methods: A retrospective analysis...

Coumarin– and Dipicolylamine–Terpenoid Hybrids as Selective Carbonic Anhydrases IX and XII Inhibitors: Mechanistic Insights and Selective Anti-Cancer Potential

Background: Carbonic Anhydrases (CAs) represent regulators of cell adaptation to hypoxia, pH regulation, and metabolic fitness. Among cancers, multiple myeloma (MM) is a plasma cell malignancy sustained by hypoxia-driven metabolic adaptation, extracellular acidification, and redox imbalance. Tight regulation of tumor extracellular pH, mediated by Carbonic Anhydrases IX and XII, is crucial for myeloma survival, progression, and stemness, making these isoforms attractive therapeutic targets. Me...

Scopri

Accesso al fulltext

no fulltext41684
open453
reserved44
restricted21
internalNetwork5
partially open1